Barchart Demo Center |
Profile | |
---|---|
Ticker Symbol | SESN |
Exchange | NASDAQ |
Contact Information |
245 FIRST STREET SUITE 1800 CAMBRIDGE, MA USA P: 617-444-8550 |
CEO/President | Thomas R. Cannell |
Earnings at a Glance | ||||
---|---|---|---|---|
Earnings | 09/30/19 -0.13 |
06/30/19 -0.67 |
03/31/19 -0.08 |
12/31/18 -0.10 |
Price Earnings Ratio | N/A | |||
EPS Growth | 32.73 | |||
Most Recent Earnings ($) | -0.13 | |||
Annual EPS ($) | -0.97 |
Business Summary | |
---|---|
Sesen Bio Inc. is a late-stage company developing next-generation antibody-drug conjugate therapies for patients with cancer. The company's product portfolio includes Vicinium(TM) which is in its clinical trial treats high-grade non-muscle invasive bladder cancer. Sesen Bio Inc. formerly known as Eleven Biotherapeutics is based in Massachusetts United States. | |
Industry/Sector | SIC-2834 Pharmaceutical Preparations Medical - Biomedical |